ASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Assoc. Prof. Pedro Barata from University Hospitals Seidman Cancer Center, USA, about the results of two adjuvant RCC studies: KEYNOTE-564; and CheckMate-914.Assoc. Prof. Barata explains the positive trial results of KEYNOTE-564, which is the first time there has been an overall survival advantage with a PD-1 inhibitor in the pure adjuvant setting in RCC. These results support adjuvant pembrolizumab as a standard of care...